MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
His death was caused by complications from multiple system atrophy, a progressive neurodegenerative disorder that affects both the central and autonomic nervous systems. Raekwon is among the many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results